We know that many of our listeners are in the depths of a tough COVID Winter in the Northern Hemisphere, so we thought we might bring you some summer cheer from Australia where the sun is shining and COVID is less of an issue! 
We have joined with our friends at PROSPECT, a prostate cancer educational initiative which has been running in Australia for eight years. to bring you a 3-part podcast summer series focussing on our favourite hot topics in prostate cancer. Today we focus on two areas with a big crossover - so-called "non-metastatic (M0)" castration-resistant prostate cancer (CRPC), and PSMA PET/CT. The past year has been a bog one for PSMA PET/CT and we are delighted to welcome two of the world's leading experts in PSMA PET/CT, Professor Michael Hofman from Peter MacCallum Cancer Centre in Melbourne, and Dr Jeremie Calais from the University of California, Los Angeles, to discuss the recent FDA approval and the data that has informed this. Plus we are joined by Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre and Chair of the PROSPECT Steering Committee, to discuss the overall survival data for androgen receptor pathway inhibitors in M0 CRPC, and to consider what wider availability of PSMA PET/CT means for this disease area. Your usual hosts are Professor Declan Murphy and Dr Renu Eapen from Peter Mac. 

PROSPECT and our GU Cast Summer Series are supported by an educational grant from Janssen Oncology in Australia.